We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Vaccibody

News List

Vaccibody signs agreement with Genentech for individualised neoantigen cancer vaccines pharmaceutical-technology
October 10, 2020
Biopharmaceutical company Vaccibody has signed an exclusive worldwide license and collaboration agreement with Genentech for the development and commercialisation of DNA-based individualised neoantigen cancer vaccines.
Vaccibody, Nektar Announce First Patient Dosed in Study for Personalized Neoantigen Cancer Vaccine americanpharmaceuticalreview
August 17, 2020
Vaccibody AS and Nektar Therapeutics announced the first patient has been dosed in the combination therapy of the Phase 1/2a study ...
Vaccibody Moving Forward with Cancer Neoantigen Vaccine Trial americanpharmaceuticalreview
April 19, 2018
PharmaJet announced Vaccibody AS has received approval to start their cancer neoantigen trial using the PharmaJet Stratis needle-free injection system.